_pmid,_doi,_publicationTitle,_year,_context,_confidence,_verdict,_usageType,assessmentName
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,"...developmental delay assessed with the Survey of Well-being of Young Children...SWYC surveys conducted on the same days, which assess developmental milestones...",0.95,Accept,Experimental Usage,Survey of Well-being of Young Children
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,...we aligned NF1 head circumference data to Survey of Well Being of Young Children (SWYC) surveys conducted on the same days...,0.95,Accept,Experimental Usage,SWYC
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,...head circumference normalized using Centers for Disease Control (CDC) growth charts...We used the LMS method from Centers for Disease Control (CDC) growth charts...,0.9,Accept,Experimental Usage,Centers for Disease Control (CDC) growth charts
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,,An assessment of sleep parameters...with an Apple Watch Ultra model 2 (application: Sleep++) was performed in all the patients with a total of three different measurements per patient,0.85,Accept,Experimental Usage,Apple Watch Ultra model 2
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,,An assessment of sleep parameters...with an Apple Watch Ultra model 2 (application: Sleep++) was performed in all the patients,0.8,Accept,Experimental Usage,Sleep++
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,"Participants were children aged 12–17 years meeting the National Institute of Health (National Institutes of Health Consensus Development Conference, 1988) diagnostic criteria for NF1.",0.85,Accept,Experimental Usage,National Institute of Health diagnostic criteria for NF1
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,The aim of this study was to investigate P300 event-related potential (ERP) associated with WM in NF1...EEG was recorded during a WM nback task.,0.8,Accept,Experimental Usage,P300 event-related potential
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,EEG was recorded during a WM nback task. The NF1 group showed poorer performance on measures of WM as compared to the control group.,0.75,Accept,Experimental Usage,WM nback task
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,"cNFs were laser-porated using the P.L.E.A.S.E.® device with the following user-defined settings: density of 10%, 5 pulses per pore, repetition rate of 300 Hz",0.85,Accept,Experimental Usage,P.L.E.A.S.E.® device
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,"visual and dermatoscopy observations (using the Dermlite DL3 [3Gen, San Jan Capistrano, CA, USA]) noting color and presence of necrosis",0.85,Accept,Experimental Usage,Dermlite DL3
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,"patients with a clinical diagnosis of NF1 according to the NIH Consensus Development Conference NF1 diagnostic criteria (NIH, 1998)",0.85,Accept,Experimental Usage,NIH Consensus Development Conference NF1 diagnostic criteria
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,"...radiography obtained using a digital cabinet X-ray system (LX-60, Faxitron X-Ray, LLC, Wheeling, IL, USA)...",0.8,Accept,Experimental Usage,"LX-60, Faxitron X-Ray, LLC"
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,"...evaluated using an ex vivo µCT imaging system (Scanco µCT 40, Scanco Medical, Bassersdorf, Switzerland)...",0.85,Accept,Experimental Usage,Scanco µCT 40
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,"...positioned on the bottom two supports such that callus was directly below the top loading point at the end of the actuator (Dynamight 8841, Instron, Canton, OH, USA)...",0.8,Accept,Experimental Usage,"Dynamight 8841, Instron"
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,"For Hemoglobin A1c measurements, blood samples were immediately measured using the A1C Now Diabetes Management HbA1C test kit (PTS Diagnostic, Indianapolis, IN)",0.85,Accept,Experimental Usage,"A1C Now Diabetes Management HbA1C test kit (PTS Diagnostic, Indianapolis, IN)"
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,"For lipoprotein, triglyceride, and cholesterol measurements, fresh serum was assayed using LDX Cholestech cartridges (Abbott, Chicago, IL)",0.8,Accept,Experimental Usage,"LDX Cholestech cartridges (Abbott, Chicago, IL)"
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,"stored at −80°C until analysis using a Pro-diabetes multiplex assay from Bio-Rad (Bio-Rad, Hercules, CA)",0.85,Accept,Experimental Usage,"Pro-diabetes multiplex assay from Bio-Rad (Bio-Rad, Hercules, CA)"
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,"transferred into a 96-well plate, and read using Thermo Scientific Multiskan GO at 570 and 600nm to obtain the absorption gradient",0.8,Accept,Experimental Usage,Thermo Scientific Multiskan GO
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,The Numerical Rating Scale-11 is a self-report measure of pain intensity that was adapted to assess PN-related pain for NF1 clinical trials.,0.85,Accept,Experimental Usage,Numerical Rating Scale-11
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,The Brief Pain Inventory Pain Interference subscale assesses the impact of pain on daily functioning in seven areas from 0 (does not interfere) to 10 (completely interfered),0.85,Accept,Experimental Usage,Brief Pain Inventory Pain Interference subscale
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,The Pediatric Quality of Life Inventory NF1 module is a disease-specific health-related quality-of-life (QOL) measure assessing 16 domains.,0.9,Accept,Experimental Usage,Pediatric Quality of Life Inventory NF1 module
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,"The cNF-Skindex is an 18-item questionnaire, including three domains: 'functioning', 'emotions', and 'symptoms'. Each item is scored on a 7-point Likert scale",0.95,Accept,Experimental Usage,cNF-Skindex
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,We aimed to adapt and validate a Dutch version of the cNF-Skindex...The Dutch cNF-Skindex demonstrated excellent feasibility and reliability,0.95,Accept,Development,Dutch cNF-Skindex
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,The EQ-5D-5L and SF-36 were used to evaluate convergent validity...The EQ-5D-5L is a brief and generic health status measure that comprises five dimensions,0.9,Accept,Experimental Usage,EQ-5D-5L
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,The EQ-5D-5L and SF-36 were used to evaluate convergent validity...The 36-item Short Form Survey (SF-36) is a generic health-related QoL measure,0.9,Accept,Experimental Usage,SF-36
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,"the Dutch cNF-Skindex was nearly identical to the Dutch version of the Skindex-16, an already validated instrument in Dutch",0.85,Accept,Citation Only,Skindex-16
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,The 2 primary outcomes were the physical health and psychological QOL domain scores of the World Health Organization Quality of Life Brief Version (WHOQOL-BREF),0.95,Accept,Experimental Usage,World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,self-reported stress and difficulties coping with NF symptoms; and (6) Perceived Stress Scale score of 6 or higher,0.9,Accept,Experimental Usage,Perceived Stress Scale
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,"To compare a mind-body skills training program, the Relaxation Response Resiliency Program for NF (3RP-NF), with a health education program",0.9,Accept,Development,Relaxation Response Resiliency Program for NF (3RP-NF)
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,with a health education program (Health Enhancement Program for NF; HEP-NF) for improvement of quality of life among adults with NF,0.9,Accept,Development,Health Enhancement Program for NF (HEP-NF)
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,We measure hearing function by DPOAE and ABR tests,0.8,Accept,Experimental Usage,DPOAE
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,We measure hearing function by DPOAE and ABR tests,0.8,Accept,Experimental Usage,ABR
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests...The hind-limb clasping test (a marker of disease progression)",0.8,Accept,Experimental Usage,hind-limb clasping test
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests...the ledge test, which evaluates coordination, is the most sensitive test",0.8,Accept,Experimental Usage,ledge test
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests...the gait test (measuring muscle function and coordination)",0.8,Accept,Experimental Usage,gait test
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,"Balance, motor strength, and coordination can be assayed by rotarod assay",0.8,Accept,Experimental Usage,rotarod assay
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,"...measurements were performed at the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, using a portable DG-HFUS device (Dermus SkinScanner, Dermus Ltd., Budapest, Hungary)...",0.85,Accept,Experimental Usage,Dermus SkinScanner
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Mice were placed 16.3 cm from a cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) and shielded with an iron collimator",0.8,Accept,Experimental Usage,"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA)"
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,Complete blood counts were performed on blood samples obtained at the time of sacrifice by cardiac puncture and analyzed immediately on a Hemavet provided by the UCSF Mouse Pathology Core.,0.85,Accept,Experimental Usage,Hemavet
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Coverslips were mounted using Vectashield with DAPI (Vector Laboratories), and visualized with a Zeiss LSM 510 Meta confocal microscope.",0.85,Accept,Experimental Usage,Zeiss LSM 510 Meta confocal microscope
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,"X-rays were taken using a piXarray 100 DSR System with Biopix Software (Version No: 1.0.6., Bioptics, Inc. Tucson, AZ)",0.85,Accept,Experimental Usage,piXarray 100 DSR System
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,"bone mineral density (BMD) of the axial bone was evaluated in vivo using pDEXA (PIXImus II; GE-Lunar Corp., Madison, WI)",0.85,Accept,Experimental Usage,PIXImus II
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,Whole axial bone was placed in the gantry of a XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner (Stratec Medizintechnik GmbH),0.9,Accept,Experimental Usage,XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,"biomechanical testing was conducted utilizing Testresourse R systems with MtestwR software version: R 1.4.2 (TestResources Inc. Shakopee, MN)",0.8,Accept,Experimental Usage,Testresourse R systems
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"Full‐Scale IQ of at least 70, as determined by the Wechsler Abbreviated Scale of Intelligence (WASI 15)",0.85,Accept,Experimental Usage,Wechsler Abbreviated Scale of Intelligence (WASI)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"the Brief Visuospatial Memory Test – Revised (BVMT, Immediate and Delayed 19 ; nonverbal declarative memory)",0.9,Accept,Experimental Usage,Brief Visuospatial Memory Test – Revised (BVMT)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,the Letter‐Number Sequencing task (LNS 20 ; working memory),0.85,Accept,Experimental Usage,Letter‐Number Sequencing task (LNS)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Hopkins Verbal Learning Test (HVLT; verbal declarative memory 22),0.85,Accept,Experimental Usage,Hopkins Verbal Learning Test (HVLT)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,WISC‐III Object Assembly (visuoconstructive ability) 23,0.85,Accept,Experimental Usage,WISC‐III Object Assembly
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"Achenbach Child Behavior Checklist (CBCL; self‐ and parent‐report) or Young Adult Self Report (YASR) 24 , 25",0.9,Accept,Experimental Usage,Achenbach Child Behavior Checklist (CBCL)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"Achenbach Child Behavior Checklist (CBCL; self‐ and parent‐report) or Young Adult Self Report (YASR) 24 , 25",0.85,Accept,Experimental Usage,Young Adult Self Report (YASR)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,the Neuropsychological Assessment Battery (NAB) Mazes 26,0.85,Accept,Experimental Usage,Neuropsychological Assessment Battery (NAB) Mazes
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency (category and letter fluency) 27,0.85,Accept,Experimental Usage,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Behavior Rating Inventory of Executive Function (BRIEF; General Executive Composite (GEC) score) 28,0.85,Accept,Experimental Usage,Behavior Rating Inventory of Executive Function (BRIEF)
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,Digit Cancellation (attention/inhibitory control) 21,0.8,Accept,Experimental Usage,Digit Cancellation
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,"A spatial working memory functional MRI paradigm, designed to be analogous to the behavioral tasks used in the mouse model",0.85,Accept,Experimental Usage,Spatial capacity working memory (SCAP) task
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,"Tumor size was classified by the Hannover and Koos classification systems. To obtain a size reference for the measured and calculated volumes, these were (sub)grouped using the Hannover",0.85,Accept,Experimental Usage,Hannover classification system
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,"Tumor size was classified by the Hannover and Koos classification systems. To obtain a size reference for the measured and calculated volumes, these were (sub)grouped using...Koos",0.85,Accept,Experimental Usage,Koos classification system
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,"the maximum linear (tumor) diameter (MLD) in axial and coronal (medial to lateral and caudal to rostral/cranial, in total four measurements per MRI) planes were measured according to the RECIST guidelines",0.8,Accept,Experimental Usage,RECIST guidelines
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,The Tinnitus Functional Index was identified as the most highly rated measure for the assessment of tinnitus in populations with neurofibromatosis type 2,0.95,Accept,Experimental Usage,Tinnitus Functional Index
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,using the Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE) form described and published previously,0.9,Accept,Experimental Usage,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE)
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,One measure was excluded (i.e. the Client Oriented Scale of Improvement-Tinnitus) because while it would be very useful for clinical settings,0.85,Accept,Citation Only,Client Oriented Scale of Improvement-Tinnitus
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,...six-item self-report questionnaire that assesses pain interference using the past 2 weeks as a recall period. Respondents rate items on a 0–6 scale...,0.95,Accept,Development,Pain Interference Index (PII)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,"...six-item PII-P is formatted and scored in the same manner as the self-report PII, with total scores ranging from 0 to 6...",0.95,Accept,Development,Pain Interference Index-Parent report (PII-P)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,...12-item self-report questionnaire that measures pain interference and has been used with children and adolescents ages 8–20 years...,0.9,Accept,Experimental Usage,Modified Brief Pain Inventory (MBPI)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,...one-item tool designed to provide an overall indicator of pain intensity at the time of the assessment. Respondents choose one of six faces...,0.9,Accept,Experimental Usage,Faces Pain Scale-Revised (FPS-R)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,...two-item visual analogue scale (VAS) developed by the authors that assesses pain intensity by asking the respondent to draw a mark on a 100-mm line...,0.85,Accept,Experimental Usage,Pain Rating Scale (PRS)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,...similar to the VAS self-report PRS in terms of item content and format. Parents are asked to draw a mark on a 100-mm line to indicate their child's level of pain...,0.85,Accept,Experimental Usage,Pain Rating Scale-Parent version (PRS-P)
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,"...adapted by our group from Ablon, asks the medical professional to rate the patient's symptoms as mild, moderate, or severe...",0.9,Accept,Experimental Usage,NF Disease Severity Scale
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,...checklist designed by a multi-disciplinary team of medical experts in NF1 at the National Institutes of Health. A medical professional notes the presence/absence of 18 diagnoses...,0.9,Accept,Experimental Usage,NF1 Disease Complications Scale
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,"We used the CatWalk XT (ver. 8, Noldus Information Technology, Wageningen, The Netherlands) system to study the functional recovery of the nerve.",0.9,Accept,Experimental Usage,CatWalk XT
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,A Grass neurostimulator was used to deliver stimuli starting with ten single electrical pulses followed by trains of pulses from 2 to 10 Hz.,0.8,Accept,Experimental Usage,Grass neurostimulator
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,images captured with a Leica DMR III microscope and CCD camera running Metamorph software,0.8,Accept,Experimental Usage,Leica DMR III microscope
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,Sections were viewed on a Jeol JEM 1230 transmission electron microscope (EM).,0.8,Accept,Experimental Usage,Jeol JEM 1230 transmission electron microscope
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,This study was conducted on a Bruker 7.0 T scanner (Bruker BioSpin GmbH).,0.8,Accept,Experimental Usage,Bruker 7.0 T scanner
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,Numerical Rating Scale-11 (NRS-11): The NRS-11 is a self-report 11-point numeric scale that assesses pain intensity,0.95,Accept,Experimental Usage,NRS-11
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,Brief Pain Inventory (BPI)-Pain Interference (PI) Scale: The BPI-PI Scale is a 7-item self-report questionnaire that measures the extent to which pain interferes,0.95,Accept,Experimental Usage,BPI-PI Scale
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,PedsQL™ NF1 Module: This scale is a self-report measure assessing NF1 disease-specific QOL,0.95,Accept,Experimental Usage,PedsQL NF1 Module
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,...radiographic tumor burden was quantified by sum of the longest tumor diameters (SLD) per RECIST 1.1 criteria...,0.9,Accept,Experimental Usage,RECIST 1.1
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,The 3-chamber SP task occurred over 2 days as described previously,0.85,Accept,Experimental Usage,3-chamber social preference task
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"mice were placed in the dark in an open chamber (40 × 40 cm, 30 cm height) for 60 minutes",0.85,Accept,Experimental Usage,open field test
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,mice were trained to identify which side of a T maze had a large reward (4 Cocoa Krispies) compared with the small reward,0.85,Accept,Experimental Usage,delay discounting task
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"a round, plastic platform (diameter, 20 cm; thickness, 2 cm) supported by a plastic rod (height, 50 cm) was used to assess the CAR",0.85,Accept,Experimental Usage,cliff avoidance reaction test
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"The objective of this study was to develop an NF1 HRQOL instrument as a module of PedsQL™ and to test for its initial feasibility, internal consistency reliability and validity in adults with NF1.",0.95,Accept,Development,PedsQL™ NF1 Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"The NF1 HRQOL format, instructions, and Likert response scale are similar to the PedsQL™ 4.0 Generic Core Scales and other PedsQL™ Disease-Specific Modules.",0.85,Accept,Experimental Usage,PedsQL™ 4.0 Generic Core Scales
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules",0.8,Accept,Experimental Usage,PedsQL™ Arthritis Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules",0.8,Accept,Experimental Usage,PedsQL™ Cancer Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules",0.8,Accept,Experimental Usage,PedsQL™ Cerebral Palsy Module
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules",0.8,Accept,Experimental Usage,PedsQL™ Family Impact Module
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,"The Impact of NF1 on Quality of Life (INF1-QOL) questionnaire was developed by a literature search for common terms, focus group (n = 6), semi-structured interviews (n = 21)",0.95,Accept,Development,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,"The EuroQol (EQ 5D) contains a global health score and covers Mobility, Self-care, Usual Activities, Pain/Discomfort, Anxiety and Depression",0.9,Accept,Experimental Usage,EuroQol (EQ 5D)
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Disease severity was determined using the Riccardi NF severity grade classification 1 to 4,0.85,Accept,Experimental Usage,Riccardi NF severity grade classification
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Adults (18 years or older) who fulfilled the diagnostic criteria for NF1 (NIH Consensus Development Conference 1987),0.8,Accept,Experimental Usage,NIH Consensus Development Conference diagnostic criteria
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,"...response of three or higher on a pain interference item (1–5 scales) from a self-report or parent-report QOL measure (Impact of Pediatric Illness Scale [ Wolters et al., 2010 ])...",0.85,Accept,Experimental Usage,Impact of Pediatric Illness Scale
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,...two scales developed by the authors for the current study assessed pain management techniques used by the patients (Pain Management Inventory) and treatment adherence...,0.8,Accept,Development,Pain Management Inventory
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,...pain management techniques used by the patients (Pain Management Inventory) and treatment adherence and study satisfaction (Post-Treatment Questionnaire)...,0.8,Accept,Development,Post-Treatment Questionnaire
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,"All participants underwent imaging of the lumbosacral plexus at the same 3-T scanner (PRISMAfit, Siemens Healthineers, Erlangen, Germany)",0.85,Accept,Experimental Usage,PRISMAfit
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,The inclusion criteria for the pain group were an average pain score of ≥ 3 on the visual analogue 0–10 scale over the previous 10 weeks,0.85,Accept,Experimental Usage,visual analogue scale
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,"All participants completed the age-appropriate digit-span subtest of the Wechsler Adult and Children Intelligence Scales (Wechsler, 2002, 2004)",0.85,Accept,Experimental Usage,Wechsler Adult and Children Intelligence Scales
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,"All participants completed...the Corsi block-tapping task (Kessels et al., 2000, 2008). Both are span tasks where the examiner presents a growing sequence",0.8,Accept,Experimental Usage,Corsi block-tapping task
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III for adults and children,0.9,Accept,Experimental Usage,WAIS-III
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III for adults and children,0.9,Accept,Experimental Usage,WISC-III
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,"We adopted the arithmetic subtest from the School Achievement Test (Stein, 1994), as an objective measure of school performance",0.85,Accept,Experimental Usage,School Achievement Test
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,Socioeconomic status (SES) was assessed using the Brazilian Criterion for Economic Classification (CCEB) according to the criteria established,0.8,Accept,Experimental Usage,Brazilian Criterion for Economic Classification (CCEB)
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,Primary outcomes were scores on a Rey complex figure test (delayed recall)...performance on the Rey complex figure test (CFT) (delayed recall; assessing nonverbal long-term memory),0.9,Accept,Experimental Usage,Rey complex figure test
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,"cancellation test (speed), prism adaptation...performance on the cancellation test (speed; assessing attention)",0.85,Accept,Experimental Usage,cancellation test
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,performance on a prism adaptation task (measurement of adaptation of the angle of hand movements in response to prism glass distortion),0.8,Accept,Experimental Usage,prism adaptation task
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,"Secondary outcome measures were scores on the cancellation test (standard deviation), Stroop color word test, block design",0.9,Accept,Experimental Usage,Stroop color word test
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,"IQ below 48, which was assessed at baseline using the Wechsler Intelligence Scale for Children–Revised, Dutch version",0.95,Accept,Experimental Usage,Wechsler Intelligence Scale for Children–Revised
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,the block design test and object assembly test of the Wechsler Intelligence Scale for Children–Revised,0.85,Accept,Experimental Usage,block design test
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,the block design test and object assembly test of the Wechsler Intelligence Scale for Children–Revised,0.85,Accept,Experimental Usage,object assembly test
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,"the Rey CFT (copy), the Beery developmental test of visual-motor integration, and the judgment of line orientation task",0.9,Accept,Experimental Usage,Beery developmental test of visual-motor integration
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,"the Beery developmental test of visual-motor integration, and the judgment of line orientation task",0.85,Accept,Experimental Usage,judgment of line orientation task
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,"Optical coherence tomography images were obtained using Cirrus HD-OCT device (Cirrus; Carl Zeiss Meditec, Dublin, CA, USA). Cirrus uses ganglion cell + inner plexiform layer...",0.9,Accept,Experimental Usage,"Cirrus HD-OCT device (Cirrus; Carl Zeiss Meditec, Dublin, CA, USA)"
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,In the youngest group VA was assessed with Teller acuity cards or Cardiff acuity cards while older children were tested with Lea or KM cards,0.85,Accept,Experimental Usage,Teller acuity cards
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,In the youngest group VA was assessed with Teller acuity cards or Cardiff acuity cards while older children were tested with Lea or KM cards,0.85,Accept,Experimental Usage,Cardiff acuity cards
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,while older children were tested with Lea or KM (Konstantin Moutakis) cards. Visual acuity was reported as logMAR units,0.85,Accept,Experimental Usage,Lea cards
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,while older children were tested with Lea or KM (Konstantin Moutakis) cards. Visual acuity was reported as logMAR units,0.85,Accept,Experimental Usage,KM (Konstantin Moutakis) cards
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Visual fields were assessed with the Humphrey Field Analyzer perimetry as previously described. The VFI is a single number that summarizes each patient's visual field status,0.9,Accept,Experimental Usage,Humphrey Field Analyzer perimetry
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,In children ≥4 years of age VA at initial visit was compared with World Health Organization Categories of Childhood VI scale for reference,0.8,Accept,Experimental Usage,World Health Organization Categories of Childhood VI scale
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,Response to treatment was monitored by using volumetric magnetic resonance imaging analysis to measure the change in size of the plexiform neurofibroma,0.85,Accept,Experimental Usage,volumetric magnetic resonance imaging analysis
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,"Adherence to the dosing schedule was assessed by administration of the Responsibility for Medication Questionnaire, by review of a patient diary",0.8,Accept,Experimental Usage,Responsibility for Medication Questionnaire
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,"Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",0.85,Accept,Experimental Usage,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0"
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"Mice were removed from the barrier facility and imaged in a small animal MRI (Varian Unity/INOVA 4.7 Tesla scanner, Varian Inc., Palo Alto, CA).",0.8,Accept,Experimental Usage,Varian Unity/INOVA 4.7 Tesla scanner
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"Digital images were captured on a Leica DMIRE2 epifluorescence microscope (Bannockburn, IL) equipped with a CCD camera and Leica FW4000 software.",0.8,Accept,Experimental Usage,Leica DMIRE2 epifluorescence microscope
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,A Likert scale questionnaire was used to survey clinicians' levels of agreement with 25 statements related to 2D and 3D tumor analyses,0.9,Accept,Experimental Usage,Likert scale questionnaire
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,Speech perception ability in background noise was evaluated in device-active and inactive conditions using the CNC-word test.,0.85,Accept,Experimental Usage,CNC-word test
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,Listening and communication ratings (LIFE-R Questionnaire) were obtained at baseline and at the end of each treatment phase.,0.9,Accept,Experimental Usage,LIFE-R Questionnaire
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,One was the Rex Gauge durometer (REX) produced by Rex Gauge LLC...We tested 2 different instruments for their ability to accurately and reproducibly measure cNF stiffness,0.95,Accept,Experimental Usage,Rex Gauge durometer
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,the other was the SkinFibroMeter (DEFLIN) made by Delfin Technologies...We tested 2 different instruments for their ability to accurately and reproducibly measure cNF stiffness,0.95,Accept,Experimental Usage,Delfin SkinFibroMeter
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,"Different models of the REX are available for varying hardness levels, with the Rex Gauge OO being specifically designed to measure the hardness of foams, gels, and animal tissue",0.9,Accept,Experimental Usage,Rex Gauge OO
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Vectra H1 (Canfield Scientific Inc, Fairfield, NJ, USA)",0.95,Accept,Experimental Usage,Vectra H1
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: ...LifeViz Micro (QuantifiCare, Biot, France)",0.95,Accept,Experimental Usage,LifeViz Micro
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: ...Cherry Imaging (Yokneam, Israel)",0.95,Accept,Experimental Usage,Cherry Imaging
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,...the compound motor action potential (CMAP) – correlating with the number of functional axons – is an indicator for axonal damage...,0.85,Accept,Experimental Usage,compound motor action potential (CMAP)
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,"...By measuring nerve properties as conduction velocity or potential amplitudes of the signal, it is possible to characterize the origin of peripheral nerve diseases...",0.8,Accept,Experimental Usage,nerve conduction velocity
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,"The water maze task was performed as previously described. Before performing the water maze task, the mice were handled for a week.",0.9,Accept,Experimental Usage,Morris water maze
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,"Motor learning was assessed with the accelerating rotarod (Ugo Basile, Comerio Varese, Italy) as previously described.",0.85,Accept,Experimental Usage,Rotarod
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,"We recorded EEG data with an EGI (Philips Neuro, Oregon, USA) 128-electrode Hydrocel Sensor Net, with the vertex electrode (approximate position of Cz in 10–20 co-ordinate system)",0.85,Accept,Experimental Usage,EGI 128-electrode Hydrocel Sensor Net
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,"The Mullen Scales of Early Learning (MSEL) is a standardised measure that assesses developmental ability across five domains: Gross Motor, Visual Reception, Fine Motor, Receptive Language and Expressive Language",0.9,Accept,Experimental Usage,Mullen Scales of Early Learning (MSEL)
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,The Autism Observation Score for Infants (AOSI) is a standardised research assessment that examines ASD traits in infants in the first two years of life,0.9,Accept,Experimental Usage,Autism Observation Score for Infants (AOSI)
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,The IBQ-R is a parent-report questionnaire consisting of 191 items and 14 scales that relate to different aspects of infant temperament,0.9,Accept,Experimental Usage,Infant Behaviour Questionnaire-Revised (IBQ-R)
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,Parents completed the MacArthur Bates Communicative Development Inventory (CDI) long form at a follow-up 14-month time point. The CDI measures early language abilities,0.9,Accept,Experimental Usage,MacArthur Bates Communicative Development Inventory (CDI)
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,All participants had their diagnosis confirmed via molecular testing of cord blood samples or clinical diagnosis based on NIH consensus criteria,0.8,Accept,Experimental Usage,NIH consensus criteria
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,"Sonographic measurement was performed using a Vevo 2100 micro-imaging system (VisualSonics, Amsterdam, Netherlands), which is a high-frequency, high-resolution digital imaging platform",0.85,Accept,Experimental Usage,Vevo 2100 micro-imaging system
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,,The disease-focused NF2 impact on quality of life (NFTI-QOL) patient questionnaire was assessed as an outcome measure for treatment in a multi-centre study.,0.95,Accept,Experimental Usage,NFTI-QOL
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,"18F-FDG PET/CT scans were all acquired to the same protocol in the same institution on one of two scanners (Discovery VCT or DST, GE Healthcare, Chicago, IL, USA)",0.85,Accept,Experimental Usage,"Discovery VCT (GE Healthcare, Chicago, IL, USA)"
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,"18F-FDG PET/CT scans were all acquired to the same protocol in the same institution on one of two scanners (Discovery VCT or DST, GE Healthcare, Chicago, IL, USA)",0.85,Accept,Experimental Usage,"DST (GE Healthcare, Chicago, IL, USA)"
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,"This study sought to develop a self-administered questionnaire in French to assess the burden of NF1 (BoN), then translate and linguistically and cross-culturally validate it",0.95,Accept,Development,Burden of NF1 (BoN) questionnaire
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,all participants were asked to complete three previously validated self-administered questionnaires: the Dermatology Life Quality Index [DLQI] questionnaire,0.9,Accept,Experimental Usage,Dermatology Life Quality Index (DLQI)
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,The PSS is the most widely used psychological instrument for measuring the perception of stress. Composed of 10 items rated from 'never' to 'often',0.9,Accept,Experimental Usage,Perceived Stress Scale (PSS)
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,"The SF12 is a short version of the SF-36, namely a generic instrument to measure population health with a physical composite score and mental composite score",0.9,Accept,Experimental Usage,SF12
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"Full-Scale IQ ≥ 70 (as determined by the Wechsler Abbreviated Scale of Intelligence [WASI]; Wechsler, 2011)",0.85,Accept,Experimental Usage,Wechsler Abbreviated Scale of Intelligence (WASI)
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"same measures from the Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV; Wechsler, 2014) for the healthy controls",0.85,Accept,Experimental Usage,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)"
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"Working memory capacity was measured behaviorally using the University of Maryland Letter–Number Sequencing (LNS) task (Gold et al., 1997)",0.8,Accept,Experimental Usage,University of Maryland Letter–Number Sequencing (LNS) task
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,"Participants viewed a visual array presenting 1, 3, 5, or 7 circles on the screen followed by a probe circle...as described in detail in Montojo et al. (2014)",0.8,Accept,Experimental Usage,Spatial capacity working memory (SCAP) task
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,"EEG data were recorded using an ActiveTwo system (BioSemi, Amsterdam, Netherlands) with 64 EEG channels in standard 10–10 system locations plus HEOG, VEOG, and mastoids",0.9,Accept,Experimental Usage,"ActiveTwo system (BioSemi, Amsterdam, Netherlands)"
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,parent-reported Adaptive Behaviour Composite (ABC) scores on the Vineland Adaptive Behaviour Scale (VABS-III),0.95,Accept,Experimental Usage,Vineland Adaptive Behaviour Scale (VABS-III)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,"...responses to the Brief Pain Inventory Short Form (BPI-SF) [ 8 ], Patient Health Questionnaire (PHQ) [ 19 ]...a pain severity aggregate score of ≥3 on the BPI-SF [ 8 ] for pain experienced in the previous 2 weeks...",0.95,Accept,Experimental Usage,Brief Pain Inventory Short Form (BPI-SF)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,"...responses to the Brief Pain Inventory Short Form (BPI-SF) [ 8 ], Patient Health Questionnaire (PHQ) [ 19 ], Structured Clinical Interview for DSM Self Report version (SCID-SR)...",0.95,Accept,Experimental Usage,Patient Health Questionnaire (PHQ)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,"...Patient Health Questionnaire (PHQ) [ 19 ], Structured Clinical Interview for DSM Self Report version (SCID-SR) [ 20 ], and Generalized Anxiety Disorder 7 Item version (GAD-7)...",0.95,Accept,Experimental Usage,Structured Clinical Interview for DSM Self Report version (SCID-SR)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,"...Structured Clinical Interview for DSM Self Report version (SCID-SR) [ 20 ], and Generalized Anxiety Disorder 7 Item version (GAD-7) [ 21 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7...",0.95,Accept,Experimental Usage,Generalized Anxiety Disorder 7 Item version (GAD-7)
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,...The PHQ-9 and GAD-7 are copyrighted by Pfizer Inc. and are freely available for research and clinical use without requiring special permissions...,0.9,Accept,Experimental Usage,PHQ-9
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Children with NF1 that screen at risk for ASD on the parent-rated Social Responsiveness Scale 2nd Edition will be invited back to complete...,0.95,Accept,Experimental Usage,Social Responsiveness Scale 2nd Edition
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,...will be invited back to complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised...,0.95,Accept,Experimental Usage,Autism Diagnostic Observation Scale 2nd Edition
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,...complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria.,0.95,Accept,Experimental Usage,Autism Diagnostic Interview-Revised
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,WPPSI-IV 10 subtests providing 5 indices and full scale IQ Y,0.9,Accept,Experimental Usage,WPPSI-IV
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,WISC-V 10 subtests providing 5 indices and full scale IQ S,0.9,Accept,Experimental Usage,WISC-V
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Sky Search Assessing the ability to selectively attend to and identify 20 visual targets among distractors S,0.85,Accept,Experimental Usage,TEA-Ch Sky Search
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Score! 10 trials assessing the ability to sustain attention by mentally counting aurally administered tones S,0.85,Accept,Experimental Usage,TEA-Ch Score!
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Shape School 4 conditions (each with 15 items) assessing inhibition, task-switching and working memory abilities in a shape and colour naming task Y",0.85,Accept,Experimental Usage,Shape School
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NEPSY-II Inhibition 6 items assessing the ability to inhibit automatic responses in favour of novel responses while quickly and efficiently naming shapes and directions S,0.85,Accept,Experimental Usage,NEPSY-II Inhibition
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Tower of Hanoi 6 items assessing set shifting, response inhibition, working memory and the ability to hold a set of rules in mind in order to reach an end-state goal Y",0.85,Accept,Experimental Usage,Tower of Hanoi
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,TEA-Ch Creature Counting 7 trials assessing the ability to accurately switch and redirect attention to count up/down S,0.85,Accept,Experimental Usage,TEA-Ch Creature Counting
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"WIAT-II Abbreviated 3 subtests assessing numerical operations, spelling and single word reading S",0.85,Accept,Experimental Usage,WIAT-II Abbreviated
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"NEPSY-II Affect Recognition 36 items assessing the ability to match facial expressions from photographs of children's faces Y, S",0.85,Accept,Experimental Usage,NEPSY-II Affect Recognition
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Benton Facial Recognition Test 13 items assessing the ability to recognise a target face from a selection of distractors S,0.85,Accept,Experimental Usage,Benton Facial Recognition Test
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"NEPSY-II ToM 21 items assessing the ability to comprehend the perspectives, intentions and beliefs of another person Y, S",0.85,Accept,Experimental Usage,NEPSY-II ToM
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Reading the Mind in the Eyes Test-Child 28 items assessing the ability to determine a person's thoughts or feelings based on a picture of only their eyes S,0.85,Accept,Experimental Usage,Reading the Mind in the Eyes Test-Child
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Faux Pas Task 20 short stories assessing the ability to identify a social faux pas S,0.85,Accept,Experimental Usage,Faux Pas Task
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Strange Stories 14 short stories assessing the ability to attribute mental states (eg, desires, beliefs or intentions) or perceive what a character knows, as well as four control comprehension stories S",0.85,Accept,Experimental Usage,Strange Stories
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CELF-Preschool-2 2 subtests assessing knowledge of grammatical rules in a sentence completion task and the ability to name objects, people and activities Y",0.85,Accept,Experimental Usage,CELF-Preschool-2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CELF-4 Formulated Sentences 28 items assessing the ability to formulate semantically and grammatically correct spoken sentences using given words (eg, car), based on an illustration S",0.85,Accept,Experimental Usage,CELF-4 Formulated Sentences
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,NEPSY-II Comprehension of Instructions 33 items assessing the ability to comprehend and follow multistep instructions of increasing complexity S,0.85,Accept,Experimental Usage,NEPSY-II Comprehension of Instructions
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"SRS-2 65 items assessing the presence and severity of ASD symptoms including social awareness, social cognition, social communication, social motivation and restricted interests and repetitive behaviour Y, S",0.9,Accept,Experimental Usage,SRS-2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,CADS 26 items assessing ADHD symptoms of impulsivity/hyperactivity and inattention Y,0.85,Accept,Experimental Usage,CADS
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Conners 3 110 items assessing ADHD symptom and comorbid disorders including oppositional defiant and conduct problems, executive functions, learning problems, peer relations and defiance/aggression S",0.85,Accept,Experimental Usage,Conners 3
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"BRIEF-Preschool 63 items assessing executive functions within the home environment, including working memory, mental set shifting, response inhibition, emotional control and planning/organisation Y",0.85,Accept,Experimental Usage,BRIEF-Preschool
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"BRIEF 86 items assessing executive functions in the home environment, including working memory, mental set shifting, response inhibition, emotional control, planning/organisation, organisation of materials, initiation and behaviour monitoring S",0.85,Accept,Experimental Usage,BRIEF
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"ABAS-3: 0–5 years 241 items assessing adaptive functioning skills, including communication, community use, preacademics, home living, health and safety, leisure, self-care, self-direction and social abilities Y",0.85,Accept,Experimental Usage,ABAS-3: 0–5 years
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"ABAS-3: 5–21 years 232 items assessing adaptive functioning skills, including communication, community use, functional academics, home living, health and safety, leisure, self-care, self-direction and social abilities S",0.85,Accept,Experimental Usage,ABAS-3: 5–21 years
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"SSIS Rating Scale 79 items assessing social skills, problem behaviours and academic competence Y, S",0.85,Accept,Experimental Usage,SSIS Rating Scale
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Sensory Profile 2 86 items assessing sensory processing, including auditory, visual, taste/smell, movement, body position, touch, plus behavioural skills including activity levels and emotional/social skills Y, S",0.85,Accept,Experimental Usage,Sensory Profile 2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CBCL: 1.5–5 years 100 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression, somatic complaints, withdrawal, sleep problems, attention problems and aggressive behaviours Y",0.85,Accept,Experimental Usage,CBCL: 1.5–5 years
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CBCL: 6–18 years 113 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression, somatic complaints, withdrawal, sleep problems, attention problems and aggressive behaviours S",0.85,Accept,Experimental Usage,CBCL: 6–18 years
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"CCC-2 70 items assessing speech, syntax, semantics, coherence, inappropriate initiation, stereotyped language, use of context, non-verbal communication, social relations and interests Y, S",0.85,Accept,Experimental Usage,CCC-2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"The ADI-R is a semistructured, standardised diagnostic interview designed to assess core aspects of ASD. The ADI-R is administered to a parent/caregiver by a trained clinician and consists of 95 items...",0.95,Accept,Experimental Usage,ADI-R
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"The ADOS-2 is a semi-structured, standardised child-direct observational assessment designed to assess reciprocal social interaction and communication, play and use of imagination.",0.95,Accept,Experimental Usage,ADOS-2
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,Neuroimaging data will be obtained on a 3-Tesla Siemens MAGNETOM Prisma MRI scanner with a 64-channel head coil at both MCRI and CHW sites.,0.9,Accept,Experimental Usage,3-Tesla Siemens MAGNETOM Prisma MRI scanner
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,"Only the MCRI site will acquire two GABA-edited magnetic resonance spectra using the localised spectroscopy sequence MEGA-PRESS, developed by CMRR...",0.85,Accept,Experimental Usage,MEGA-PRESS
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,The PlexiQoL questionnaire is a disease-specific QoL measure for adults with NF1-associated plexiform neurofibromas. The aim of this study was to adapt and validate a Dutch version,0.95,Accept,Development,PlexiQoL
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,The Nottingham Health Profile (NHP) questionnaire was used as comparator questionnaire to evaluate convergent validity,0.9,Accept,Experimental Usage,Nottingham Health Profile (NHP)
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,Gross motor coordination function was evaluated using the Rotarod (Med Associates),0.9,Accept,Experimental Usage,Rotarod
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,Imaging was performed with a 9.4-T BioSpec 94/20 USR MRI (Bruker BioSpin MRI),0.9,Accept,Experimental Usage,BioSpec 94/20 USR MRI
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children),0.9,Accept,Experimental Usage,WAIS-III
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children),0.9,Accept,Experimental Usage,WISC-III
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,The Nine-Hole Peg Test was performed as a measure of finger dexterity. It measures the time (in seconds) needed to complete the test,0.85,Accept,Experimental Usage,Nine-Hole Peg Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,The Rey-Osterrieth Complex Figure Test was implemented as a measure of the visuospatial cognitive domain,0.85,Accept,Experimental Usage,Rey-Osterrieth Complex Figure Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,Immediate (A6) and delayed recalls (A7) of the Brazilian-Portuguese version of the Rey Auditory-Verbal Learning Test (RAVLT) were taken as measures,0.85,Accept,Experimental Usage,Rey Auditory-Verbal Learning Test (RAVLT)
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,"Assessment of this cognitive domain was performed by a Category Fluency Test (""animals"")",0.8,Accept,Experimental Usage,Category Fluency Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,"and by Lexical Fluency Test letters (F, A, and S)",0.8,Accept,Experimental Usage,Lexical Fluency Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,The Five Digits Test (FDT) is a numeric-Stroop paradigm designed to assess attentional processes,0.85,Accept,Experimental Usage,Five Digits Test (FDT)
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,"For working memory evaluation, we used the Digit Span according to the WAIS-III or WISC-III, and the Corsi block-tapping task",0.8,Accept,Experimental Usage,Corsi block-tapping task
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,The Tower of London Test was used as a measure of Planning Skills,0.8,Accept,Experimental Usage,Tower of London Test
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,"Resting-state 18F-FDG PET/CT brain images were acquired in a GE Discovery 690 (GE Healthcare, Millwalke, EUA) scanner",0.9,Accept,Experimental Usage,GE Discovery 690
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,We have assessed NF2 clinical phenotype in 142 patients in relation to the UK NF2 Genetic Severity Score to validate its use as a clinical and research tool.,0.95,Accept,Experimental Usage,UK NF2 Genetic Severity Score
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,"Quality of life was assessed using the 8-item NF2 disease-specific quality of life score (0–24), with good internal reliability (Cronbach's α=0.87).",0.9,Accept,Experimental Usage,8-item NF2 disease-specific quality of life score
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,all patients known to the Oxford NF2 centre who met the Manchester NF2 diagnostic criteria and consented to genetic testing were analysed,0.85,Accept,Experimental Usage,Manchester NF2 diagnostic criteria
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,"Hearing grade was assigned based on a score of 1–6, as used within the English NF2 service to indicate suitability for a hearing implant",0.8,Accept,Experimental Usage,hearing grade score of 1–6
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Gait was analyzed using the Noldus Cat-Walk XT system as before,0.9,Accept,Experimental Usage,Noldus Cat-Walk XT system
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,"We administered the Portuguese adapted version of the Wechsler Intelligence Scale for Children (WISC-III), in all participants with NF1",0.95,Accept,Experimental Usage,Wechsler Intelligence Scale for Children (WISC-III)
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules",0.95,Accept,Experimental Usage,PedsQL™ Generic 4.0
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules",0.95,Accept,Experimental Usage,PedsQL™ Neuromuscular 3.0
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,quality of life (Pediatric Quality of Life and Child Behavior Checklist for ages 6–18). ...The Child Behavior Checklist for ages 6–18 or CBCL/6‐18 (©ASEBA 2020),0.95,Accept,Experimental Usage,CBCL/6-18
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,Body fat was measured using the MC‐780MA Tanita Tokyo body composition analyzer. The MC‐780MA body composition analyzer divides the human body into five sections,0.9,Accept,Experimental Usage,MC-780MA Tanita Tokyo body composition analyzer
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"Maximal isometric strength of three muscle groups...were tested using hand‐held dynamometry by a trained clinical evaluator (Citec; CIT Tehcnics, Harren, the Netherlands)",0.85,Accept,Experimental Usage,Citec hand-held dynamometer
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"Fine motor endurance was evaluated by the Handwriting Speed Test (Wallen et al., 1996) that gives a raw score in letters per minute",0.9,Accept,Experimental Usage,Handwriting Speed Test
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,"gross motor endurance by the 6MWT, which was completed barefoot on a point‐to‐point, 25‐m long, flat, straight, hard surfaced track",0.9,Accept,Experimental Usage,6-minute-walk test
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,...provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains (cognitive debriefing)...,0.9,Accept,Experimental Usage,Numeric Rating Scale-11
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,"...The self-report NRS-11 has been used in numerous studies, including as a primary outcome measure, to assess pain intensity...",0.9,Accept,Experimental Usage,NRS-11
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,...provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains...,0.9,Accept,Experimental Usage,Pain Interference Index
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,...The PII is a 6-item questionnaire developed to assess the extent to which pain interferes with six different aspects of daily functioning...,0.9,Accept,Experimental Usage,PII
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,"...the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF)...",0.95,Accept,Development,PAINS-pNF
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,...and the Pain Interference Index for plexiform neurofibromas (PII-pNF) for administration on a mobile app or web-based platform...,0.95,Accept,Development,PII-pNF
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,"QOL was assessed with the PedsQL 4.0 Generic Core Scales at baseline and prior to cycles 4, 8, 12, 18, and 24. This 23-item questionnaire yields subscale scores...",0.95,Accept,Experimental Usage,PedsQL 4.0 Generic Core Scales
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,Toxicity was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0.,0.9,Accept,Experimental Usage,NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,"Scans were obtained on a dedicated PET/CT scanner (Biograph mCT 40; Siemens Healthineers, Erlangen, Germany)",0.9,Accept,Experimental Usage,Biograph mCT 40 (Siemens Healthineers)
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)",0.95,Accept,Experimental Usage,SF-36
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)",0.95,Accept,Experimental Usage,EQ-5D-5L
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)",0.95,Accept,Experimental Usage,PROMIS pain interference
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2),0.95,Accept,Experimental Usage,PedsQL NF1 module
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2),0.95,Accept,Experimental Usage,NFTI-QOL
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,the clinicians also rated the disease visibility using the Ablon visibility index,0.9,Accept,Experimental Usage,Ablon visibility index
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,physicians also completed the House and Brackmann facial nerve scale that rates facial nerve impairments,0.9,Accept,Experimental Usage,House and Brackmann facial nerve scale
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,"PROMIS pain interference short form 8a: This is an 8-item questionnaire, assessing how pain affects social, cognitive, physical",0.95,Accept,Experimental Usage,PROMIS pain interference short form 8a
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,"PedsQL NF1 adult module: This is a 74-item self-reported measure, specifically developed for NF1",0.95,Accept,Experimental Usage,PedsQL NF1 adult module
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,Visual acuity (n=20 mice per group) was assessed using the virtual optokinetic system (VOS) under photopic conditions (1.8 log cd/m 10 2 ),0.85,Accept,Experimental Usage,virtual optokinetic system (VOS)
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Closed mid-diaphyseal fracture of the tibia was created by three-point bending with an Einhorn device,0.8,Accept,Experimental Usage,Einhorn device
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"μCT analyses were performed using a high-resolution benchtopScancoμ CT 40 system (Scanco Medical, Bassersdorf, Switzerland)",0.9,Accept,Experimental Usage,ScancoμCT 40 system
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Three-point-bending was accomplished in displacement control on an InstronDynamight 4481 servo-hydraulic material testing apparatus,0.9,Accept,Experimental Usage,InstronDynamight 4481
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,Performance tasks (Cogstate) and observer-reported functioning (BRIEF) were the primary outcomes...participants completed the cognitive assessment (Cogstate),0.9,Accept,Experimental Usage,Cogstate
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,observer-reported functioning (BRIEF) were the primary outcomes...a consistent parent completed a questionnaire of executive functioning (Behavior Rating Inventory of Executive Function; BRIEF),0.9,Accept,Experimental Usage,BRIEF
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,a consistent parent completed a questionnaire of executive functioning (Behavior Rating Inventory of Executive Function; BRIEF),0.85,Accept,Experimental Usage,Behavior Rating Inventory of Executive Function
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,"individual-level analyses (Reliable Change Index, RCI) were used...using a Reliable Change Index (RCI) methodology, which generates a confidence interval",0.8,Accept,Experimental Usage,Reliable Change Index
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,"A Wood's lamp, which makes CALMs more visible, was used for CALM counting in CALM1, but not in CALM2.",0.8,Accept,Experimental Usage,Wood's lamp
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,"Mice were placed in a cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) animal irradiator and shielded with an iron collimator",0.8,Accept,Experimental Usage,cesium-137 source (J.L. Shepherd & Associates)
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,"Photographs of histology were taken with an Olympus BX41 microscope, using Olympus UplanFl 10X/0.3 and 20X/0.5 objectives.",0.8,Accept,Experimental Usage,Olympus BX41 microscope
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,An attached Olympus DP72 camera and Adobe Photoshop CS2 were used to capture the images.,0.8,Accept,Experimental Usage,Olympus DP72 camera
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,"Assay C2557613_10 was used to genotype using the Taq amplification method in a 7900 HT Fast Real-Time PCR system (Applied Biosystems, USA).",0.85,Accept,Experimental Usage,7900 HT Fast Real-Time PCR system (Applied Biosystems)
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"The 22-point (0–21) Basso, Beattie, and Bresnahan (BBB) open-field locomotor test was used to assess hindlimb locomotor function",0.9,Accept,Experimental Usage,BBB open-field locomotor test
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Motor function and motor learning were evaluated by rotarod apparatus. 1 hr before the rotarod test, mice were transferred from the holding room",0.9,Accept,Experimental Usage,Rotarod apparatus
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,The Distress Thermometer (DT) was designed as a brief screening tool to assess for distress in adult cancer patients...adapted DT to screen for distress in a pediatric oncology inpatient setting,0.95,Accept,Experimental Usage,Distress Thermometer (DT)
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,"The CDI–S (Kovacs, 1992) is a 10-item self-report measure for depression in children, ages 7 to 17 years. The CDI was completed by all patients ages 7–17.",0.9,Accept,Experimental Usage,Children's Depression Inventory (CDI-S)
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,"The CDI Parent Version (CDI-P) is derived directly from the CDI, is scored identically and has similar psychometric properties...The CDI-P was completed by caregivers of all patients",0.9,Accept,Experimental Usage,Children's Depression Inventory Parent Version (CDI-P)
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,"The BSI-18 (Derogatis et al., 2004) is an 18-item self-report measure to screen for psychological distress and psychiatric disorders...patients ages 18–21 were administered the Depression dimension",0.9,Accept,Experimental Usage,Brief Symptom Inventory 18 (BSI-18)
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Medical providers completed a Lansky score for patients 17 years and younger...These scores indicate the disease severity and functional capabilities of the patient,0.85,Accept,Experimental Usage,Lansky score
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,Medical providers completed...a Karnofsky score for patients 18 years and older. These scores indicate the disease severity and functional capabilities of the patient,0.85,Accept,Experimental Usage,Karnofsky score
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,"Patients, primary caregivers, and the child's primary medical provider rated on a scale of 1–4 how easy or difficult the DT was to complete...The DT Acceptability and Feasibility Scales were developed by the study investigators",0.8,Accept,Development,Distress Thermometer Acceptability and Feasibility Scales
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,The PlexiQoL is the first disease-specific PRO assessing the ability of adults with NF-1 associated pNFs to meet their basic human needs.,1.0,Accept,Development,PlexiQoL
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,"The comparator measure used in the UK was the Nottingham Health Profile (NHP; Hunt et al., 1981)",0.9,Accept,Experimental Usage,Nottingham Health Profile (NHP)
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,"the Short Form‐36 (SF‐36; Ware & Sherbourne, 1992) was used in the US. These are generic measures of subjective health status",0.9,Accept,Experimental Usage,Short Form-36 (SF-36)
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,patients were recruited through the Children's Tumor Foundation Patient Registry (https://nfregistry.patientcrossroads.org),0.8,Accept,Experimental Usage,Children's Tumor Foundation Patient Registry
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,QOL was assessed using the Impact of Pediatric Illness (IPI) Scale for children 6–18 years of age. The child's primary caregiver completed the proxy Parent Form and children answered either the self-report Child (ages 6–10 years) or Adolescent (ages 11–18 years) Form,0.95,Accept,Experimental Usage,Impact of Pediatric Illness (IPI) Scale
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,Adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,0.9,Accept,Experimental Usage,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,"STIR MRI of up to three clinically relevant index PN was performed for volumetric analysis as previously described prior to the start of cycles 1, 4, 7, 10, and then after every six cycles",0.85,Accept,Experimental Usage,STIR MRI
PMID:36604703,10.1186/s13023-022-02607-z,The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.,,The NFTI-QOL questionnaire has produced useful results in English-speaking cohorts. The aim of this study was to produce and validate a German version of the NFTI-QOL,0.95,Accept,Experimental Usage,NFTI-QOL
PMID:36604703,10.1186/s13023-022-02607-z,The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.,,A link to an online survey encompassing the NFTI-QOL-D and the PHQ-9 depression questionnaire was then sent to 97 patients with NF2 by email,0.95,Accept,Development,NFTI-QOL-D
PMID:36604703,10.1186/s13023-022-02607-z,The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.,,"An online survey was created including the NFTI-QOL-D and the German version of the PHQ-9 questionnaire (9-item patient health questionnaire, a tool for the assessment of depression)",0.9,Accept,Experimental Usage,PHQ-9
PMID:38170419,10.1007/s11136-023-03574-z,Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric stigma: skin item banks.,,...we re-named this instrument the PROMIS Pediatric Stigma Measure (PPS). Sample and data sources Data obtained from 860 children aged 8–17 years were analyzed...,0.95,Accept,Development,PROMIS Pediatric Stigma Measure (PPS)
PMID:38170419,10.1007/s11136-023-03574-z,Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric stigma: skin item banks.,,...To develop the PROMIS Pediatric Stigma (PPS) and Skin (PPS-Skin) by constructing a common metric for measuring stigma in children with various conditions...,0.95,Accept,Development,PROMIS Pediatric Stigma: Skin (PPS-Skin)
PMID:38170419,10.1007/s11136-023-03574-z,Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric stigma: skin item banks.,,"...Children with epilepsy, pNF and MD (sample-1) completed the original 18-item Neuro-QoL Stigma, while children with cancer and skin conditions...",0.9,Accept,Experimental Usage,Neuro-QoL Pediatric Stigma
PMID:34604751,10.1093/noajnl/vdab116,Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1.,,"we will be basing criteria for treatment on the clinical MR-HIFU system available at CNH (Profound Sonalleve V2; Profound Medical Inc., Mississauga, Ontario, Canada)",0.85,Accept,Experimental Usage,"Profound Sonalleve V2 (Profound Medical Inc., Mississauga, Ontario, Canada)"
PMID:34604751,10.1093/noajnl/vdab116,Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1.,,Patients from CNH were enrolled on clinical trial NCT03820778 evaluating the use of whole-body MRI for identifying ANNUBP in patients with NF1.,0.8,Accept,Experimental Usage,NCT03820778
PMID:34604751,10.1093/noajnl/vdab116,Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1.,,"Patients from NCI were enrolled on clinical trial NCT00924196, a natural history study of patients with NF1.",0.8,Accept,Experimental Usage,NCT00924196
PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,"A non-contrast enhanced, full body screening CT was acquired at TP1 and TP3 using a Siemens SOMATOM Force CT scanner (Siemens Healthcare, Forcheim, Germany)...",0.8,Accept,Experimental Usage,Siemens SOMATOM Force CT scanner
PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,"...using a Siemens SOMATOM Force CT scanner (Siemens Healthcare, Forcheim, Germany) or a GE Discovery MI PET/CT (GE Healthcare, Waukesha, WI)...",0.8,Accept,Experimental Usage,GE Discovery MI PET/CT
PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,MR imaging was performed at all timepoints using a 3.0 T General Electric Discovery MR750w...,0.8,Accept,Experimental Usage,General Electric Discovery MR750w
PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,...mechanically ventilated using a Primer SP MRI-Compatible Veterinary Anesthesia Ventilator (DRE Veterinary)...,0.75,Accept,Experimental Usage,Primer SP MRI-Compatible Veterinary Anesthesia Ventilator
PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,"bone mineral density (BMD) of the tibial diaphysis was evaluated in vivo using pDEXA (PIXImus II; GE-Lunar Corp., Madison, WI)",0.85,Accept,Experimental Usage,PIXImus II
PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,"high-resolution desktop microcomputed tomography imaging system (μCT-20; Scanco Medical AG, Basserdorf, Switzerland)",0.85,Accept,Experimental Usage,μCT-20
PMID:25475340,10.1186/s13023-014-0202-9,Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.,,"...two photographs were taken from each paper frame, using a digital camera (Sony Cyber-shot DSC-W30, Tokyo, Japan)...",0.85,Accept,Experimental Usage,Sony Cyber-shot DSC-W30
PMID:25475340,10.1186/s13023-014-0202-9,Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.,,"...a new methodology for skin neurofibromas quantification using paper frames...paper frames, with a central square measuring 100 cm2...",0.95,Accept,Development,paper frames method
PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,Word recognition is measured using 50-item CID-W22 (Central Institute for the Deaf; Ira Hirsh recording) monosyllable wordlists and ranges from 0% to 100%.,0.9,Accept,Experimental Usage,CID-W22 (Central Institute for the Deaf; Ira Hirsh recording) monosyllable wordlists
PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,"Other standardized monosyllable recorded lists may be used including NU#6, CNC and others as long as similar performance-to-intensity functions can be shown for the recording used.",0.8,Accept,Experimental Usage,NU#6
PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,"Other standardized monosyllable recorded lists may be used including NU#6, CNC and others as long as similar performance-to-intensity functions can be shown for the recording used.",0.8,Accept,Experimental Usage,CNC
PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,"...were scanned with FLT and FDG using a high-resolution research tomograph (HRRT, Siemens) and a Siemens Biograph TrueV PET-CT...",0.85,Accept,Experimental Usage,"high-resolution research tomograph (HRRT, Siemens)"
PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,"...using a high-resolution research tomograph (HRRT, Siemens) and a Siemens Biograph TrueV PET-CT, with and without resolution modeling...",0.85,Accept,Experimental Usage,Siemens Biograph TrueV PET-CT
PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,We measured resilience factors via the Measure of Current Status-A (adaptive coping)...It is comprised of 13 items with four subscales,0.95,Accept,Experimental Usage,Measure of Current Status-A (MOCS-A)
PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,Cognitive and Affective Mindfulness Scale-Revised (mindfulness)...It is comprised of 12-items rated on a scale from 1 to 4,0.95,Accept,Experimental Usage,Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,Gratitude Questionnaire-6 (gratitude)...It is a 6-item measure rated on a scale from 1 to 7,0.95,Accept,Experimental Usage,Gratitude Questionnaire-6 (GQ-6)
PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,Life Orientation Test Optimism Scale (optimism)...It is an 8-item measure rated on a scale from 0 to 4,0.95,Accept,Experimental Usage,Life Orientation Test Optimism Scale (LOT)
PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,Medical Outcomes Study Social Support Survey (perceived social support)...It is a 19-item measure with four domains,0.95,Accept,Experimental Usage,Medical Outcomes Study Social Support Survey (MOS)
PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,score of 6 or higher on the Patient Stress Scale-4 items,0.9,Accept,Experimental Usage,Patient Stress Scale-4 items
PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,"Relaxation Response Resiliency Program - Neurofibromatosis (3RP-NF), a mind-body resilience program for people with NF",0.9,Accept,Development,3RP-NF
PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,health education control (HEP-NF)...The HEP-NF program was adapted from the original HEP and NF-specific materials,0.9,Accept,Development,HEP-NF
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,The Hospital Depression and Anxiety Score (HADS) was used to screen for anxiety and depression,0.95,Accept,Experimental Usage,Hospital Depression and Anxiety Score (HADS)
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,"Pain perception was assessed by the PainDETECT questionnaire, which provides high sensitivity, specificity, and positive predictive value to detect neuropathic pain",0.95,Accept,Experimental Usage,PainDETECT questionnaire
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,"In order to examine stable traits of patients' personality the multidimensional ""Freiburger Persönlichkeitsinventar"" (FPI) was used",0.9,Accept,Experimental Usage,Freiburger Persönlichkeitsinventar (FPI)
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,"By means of the Symptom Checklist-90-R (SCL-90-R), the patients' subjective strain through physical and psychological disorders were measured",0.95,Accept,Experimental Usage,Symptom Checklist-90-R (SCL-90-R)
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,The German Version of the SF-36 health survey was utilized to assess health-related quality of life,0.95,Accept,Experimental Usage,SF-36 health survey
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,"Conventional electrodiagnostic testing...was performed in the neurophysiology laboratory...using a Nihon Kohden Neuropack X1 (Rosbach v.d.H., Germany)",0.85,Accept,Experimental Usage,Nihon Kohden Neuropack X1
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,"We delivered brief infrared laser stimuli...using a thulium YAG laser (wavelength 2 μm, StarMedTec, Starnberg, Germany)",0.85,Accept,Experimental Usage,thulium YAG laser
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,"Additional high-resolution microstructural MR neurography was performed...at 3.0 Tesla (Magnetom Verio, Siemens, Erlangen, Germany)",0.85,Accept,Experimental Usage,Magnetom Verio
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,The FACE-Q Craniofacial Module-Appearance Distress scale was the top-rated measure for potential use in neurofibromatosis 1 clinical trials.,0.95,Accept,Experimental Usage,FACE-Q Craniofacial Module-Appearance Distress scale
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,Our revised Patient-Reported Outcome Rating and Acceptance Tool for Endpoints then was used to evaluate each published patient-reported outcome measures,0.9,Accept,Experimental Usage,Patient-Reported Outcomes Rating and Acceptance Tool for Endpoints
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,"yielded 49 manuscripts describing seven instruments: the Perceived Stigma Questionnaire, Social Comfort Questionnaire, Body Esteem Scale",0.85,Accept,Experimental Usage,Perceived Stigma Questionnaire
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,"the Perceived Stigma Questionnaire, Social Comfort Questionnaire, Body Esteem Scale for Adolescents and Adults",0.85,Accept,Experimental Usage,Social Comfort Questionnaire
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,"Social Comfort Questionnaire, Body Esteem Scale for Adolescents and Adults, Subjective Happiness Scale",0.85,Accept,Experimental Usage,Body Esteem Scale for Adolescents and Adults
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,"Body Esteem Scale for Adolescents and Adults, Subjective Happiness Scale, Derriford Appearance Scale",0.85,Accept,Experimental Usage,Subjective Happiness Scale
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,"Subjective Happiness Scale, Derriford Appearance Scale, The Self-Description Questionnaire I and Skindex",0.85,Accept,Experimental Usage,Derriford Appearance Scale
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,"Derriford Appearance Scale, The Self-Description Questionnaire I and Skindex",0.85,Accept,Experimental Usage,Self-Description Questionnaire I
PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,The Self-Description Questionnaire I and Skindex. In reviewing the measures retrieved,0.85,Accept,Experimental Usage,Skindex
PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,All the participants but one were right-handed as assessed by the Edinburgh Handedness Inventory [29],0.85,Accept,Experimental Usage,Edinburgh Handedness Inventory
PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,Intellectual function was assessed by using the Portuguese-adapted version of the Wechsler Adult Intelligence Scale-3rd edition (WAIS-III) [30],0.9,Accept,Experimental Usage,Wechsler Adult Intelligence Scale-3rd edition (WAIS-III)
PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,All the participants performed the standard Stroop Colour and Word Test [31] composed by two congruent conditions [word (W) and colour (C)] and one incongruent,0.85,Accept,Experimental Usage,Stroop Colour and Word Test
PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,"Behavioural data (tapping timings) were recorded using the MRI-compatible response box Lumina LP-400 (Cedrus Corporation, San Pedro, CA, USA)",0.85,Accept,Experimental Usage,Lumina LP-400
PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,"Electroencephalographic signals were recorded using a 64 electrodes cap (QuickCap, NeuroScan, USA) with electrodes placed according to the extended 10/20 system",0.8,Accept,Experimental Usage,QuickCap
PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,"The continuous signal was amplified and recorded at a sampling rate of 1 kHz, low pass filter at 200 Hz, through a SynAmps2/RT amplifier",0.85,Accept,Experimental Usage,SynAmps2/RT amplifier
PMID:28644838,10.1371/journal.pone.0178639,"Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study.",,"In 2012, the Children's Tumor Foundation created a web-based patient-entered database, the NF Registry, to inform patients of research opportunities",0.95,Accept,Development,NF Registry
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,"The Tucker-Davis Technologies (TDT) BioSigRZ system, with an RZ6 digital/analog converter (TDT), was used to produce and record responses",0.85,Accept,Experimental Usage,Tucker-Davis Technologies BioSigRZ system
PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,"...functional improvements, as reflected by increased Japanese Orthopaedic Association/modified Japanese Orthopaedic Association scores...",0.85,Accept,Experimental Usage,Japanese Orthopaedic Association
PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,"...functional improvements, as reflected by increased Japanese Orthopaedic Association/modified Japanese Orthopaedic Association scores...",0.85,Accept,Experimental Usage,modified Japanese Orthopaedic Association
PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,"...decreased Visual Analog Scale scores, and reduced Neck Disability Index scores...",0.9,Accept,Experimental Usage,Visual Analog Scale
PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,"...decreased Visual Analog Scale scores, and reduced Neck Disability Index scores...",0.9,Accept,Experimental Usage,Neck Disability Index
PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,"...assessed the methodological quality of the full text using the Joanna Briggs Institute critical appraisal tool, which evaluates the quality of observational studies...",0.8,Accept,Experimental Usage,Joanna Briggs Institute critical appraisal tool
PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,"The Social Responsiveness Scale, second edition (SRS-2) is an extensively validated, 65-item quantitative trait measure designed to ascertain the presence and severity of social communicative and repetitive behaviors that characterize ASD.",0.95,Accept,Experimental Usage,"Social Responsiveness Scale, second edition (SRS-2)"
PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,"Four versions of the Conners ADHD rating scales were used across sites: Conners, third edition, Conners Adult ADHD Rating Scale, Conners Parent Rating Scale–Revised, and Conners ADHD/DSM-IV Scales.",0.9,Accept,Experimental Usage,"Conners, third edition"
PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,"Four versions of the Conners ADHD rating scales were used across sites: Conners, third edition, Conners Adult ADHD Rating Scale, Conners Parent Rating Scale–Revised, and Conners ADHD/DSM-IV Scales.",0.9,Accept,Experimental Usage,Conners Adult ADHD Rating Scale
PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,"Four versions of the Conners ADHD rating scales were used across sites: Conners, third edition, Conners Adult ADHD Rating Scale, Conners Parent Rating Scale–Revised, and Conners ADHD/DSM-IV Scales.",0.9,Accept,Experimental Usage,Conners Parent Rating Scale–Revised
PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,"Four versions of the Conners ADHD rating scales were used across sites: Conners, third edition, Conners Adult ADHD Rating Scale, Conners Parent Rating Scale–Revised, and Conners ADHD/DSM-IV Scales.",0.9,Accept,Experimental Usage,Conners ADHD/DSM-IV Scales
